» Articles » PMID: 15286002

BMPR-II Heterozygous Mice Have Mild Pulmonary Hypertension and an Impaired Pulmonary Vascular Remodeling Response to Prolonged Hypoxia

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Heterozygous mutations of the bone morphogenetic protein type II receptor (BMPR-II) gene have been identified in patients with primary pulmonary hypertension. The mechanisms by which these mutations contribute to the pathogenesis of primary pulmonary hypertension are not fully elucidated. To assess the impact of a heterozygous mutation of the BMPR-II gene on the pulmonary vasculature, we studied mice carrying a mutant BMPR-II allele lacking exons 4 and 5 (BMPR-II(+/-) mice). BMPR-II(+/-) mice had increased mean pulmonary arterial pressure and pulmonary vascular resistance compared with their wild-type littermates. Histological analyses revealed that the wall thickness of muscularized pulmonary arteries (<100 mum in diameter) and the number of alveolar-capillary units were greater in BMPR-II(+/-) than in wild-type mice. Breathing 11% oxygen for 3 wk increased mean pulmonary arterial pressure, pulmonary vascular resistance, and hemoglobin concentration to similar levels in BMPR-II(+/-) and wild-type mice, but the degree of muscularization of small pulmonary arteries and formation of alveolar-capillary units were reduced in BMPR-II(+/-) mice. Our results suggest that, in mice, mutation of one copy of the BMPR-II gene causes pulmonary hypertension but impairs the ability of the pulmonary vasculature to remodel in response to prolonged hypoxic breathing.

Citing Articles

ATP13A3 variants promote pulmonary arterial hypertension by disrupting polyamine transport.

Liu B, Azfar M, Legchenko E, West J, Martin S, Van den Haute C Cardiovasc Res. 2024; 120(7):756-768.

PMID: 38626311 PMC: 11135649. DOI: 10.1093/cvr/cvae068.


Insights into bone morphogenetic proteins in cardiovascular diseases.

Ye D, Liu Y, Pan H, Feng Y, Lu X, Gan L Front Pharmacol. 2023; 14:1125642.

PMID: 36909186 PMC: 9996008. DOI: 10.3389/fphar.2023.1125642.


The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.

Boucherat O, Agrawal V, Lawrie A, Bonnet S Circ Res. 2022; 130(9):1466-1486.

PMID: 35482834 PMC: 9060385. DOI: 10.1161/CIRCRESAHA.121.319971.


New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis.

Aldred M, Morrell N, Guignabert C Circ Res. 2022; 130(9):1365-1381.

PMID: 35482831 PMC: 9897592. DOI: 10.1161/CIRCRESAHA.122.320084.


Compensatory roles of Protein Related to DAN and Cerberus (PRDC) decrease in pulmonary arterial hypertension.

He T, Zhang J, Qiao T, Zhang Z, Han H, Yang C Int J Biol Sci. 2022; 18(6):2372-2391.

PMID: 35414785 PMC: 8990474. DOI: 10.7150/ijbs.70247.